Basit öğe kaydını göster

dc.contributor.authorKORKMAZ, Taner
dc.contributor.authorBese, Nuran
dc.contributor.authorİNCE, Ümit
dc.contributor.authorURAS, Cihan
dc.contributor.authorCabioglu, Neslihan
dc.contributor.authorTOKAT, Fatma
dc.contributor.authorER, Ozlem
dc.contributor.authorKARA, Halil
dc.date.accessioned2023-02-21T09:59:29Z
dc.date.available2023-02-21T09:59:29Z
dc.date.issued2022
dc.identifier.citationURAS C., Cabioglu N., TOKAT F., ER O., KARA H., KORKMAZ T., Bese N., İNCE Ü., "Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up", BMC Cancer, cilt.22, sa.1, 2022
dc.identifier.issn1471-2407
dc.identifier.othervv_1032021
dc.identifier.otherav_39c9c903-bbf4-4119-b326-978e2599ae99
dc.identifier.urihttp://hdl.handle.net/20.500.12627/187986
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/39c9c903-bbf4-4119-b326-978e2599ae99/file
dc.identifier.urihttps://doi.org/10.1186/s12885-022-10308-w
dc.description.abstract© 2022, The Author(s).Background: Recent studies have shown a lower likelihood of locoregional recurrences in patients with a low 21-gene recurrence score (RS). In this single-institution study, we investigated whether there are any associations between different cutoff values of 21-gene RS, histopathological factors, and outcome in patients with long-term follow-up. Methods: The study included 61 patients who had early-stage (I-II) clinically node-negative hormone receptor-positive and HER2-negative breast cancer and were tested with the 21-gene RS assay between February 2010 and February 2013. Demographic, clinicopathological, treatment, and outcome characteristics were analyzed. Results: The median age was 48 years (range, 29–72 years). Patients with high histologic grade (HG), Ki-67 ≥ 25%, or Ki-67 ≥ 30% were more likely to have intermediate/high RS (≥ 18). Based on the 21-gene RS assay, only 19 patients (31%) received adjuvant chemotherapy. At a median follow-up of 112 months, 3 patients developed locoregional recurrences (4.9%), which were treated with endocrine therapy alone. Among patients treated with endocrine treatment alone (n = 42), the following clinicopathological characteristics were not found to be significantly associated with 10-year locoregional recurrence free survival (LRRFS): age 11. However, patients with RS ≥ 16 had significantly poorer 10-year LRRFS compared to those with RS < 16 (75% vs. 100%, respectively; p = 0.039). Conclusions: The results suggest that patients with clinically node-negative disease and RS ≥ 16 are more likely to benefit from adjuvant chemotherapies. However, those with RS < 16 have an excellent outcome and local control in long-term follow-up with endocrine treatment alone.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectONKOLOJİ
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectGENETİK VE KALITIM
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectGenetik
dc.subjectKanser Araştırmaları
dc.subjectOnkoloji
dc.subjectTıbbi Genetik
dc.subjectYaşam Bilimleri
dc.subjectSitogenetik
dc.subjectSağlık Bilimleri
dc.titleFavorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up
dc.typeMakale
dc.relation.journalBMC Cancer
dc.contributor.departmentAcıbadem Mehmet Ali Aydınlar Üniversitesi , Tıp Fakültesi , Cerrahi Tıp Bilimleri Bölümü
dc.identifier.volume22
dc.identifier.issue1
dc.contributor.firstauthorID4091330


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster